In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo
Acta Pol Pharm , 2014, 71(6): 954-958
This reflects the true cost of pharmaceutical-grade, properly sourced peptidesnot the artificially low prices of unregulated grey-market products that cut corners on quality
Okabayashi T et al
On Wednesday 4/1/26, the Food and Drug Administration (FDA) approved Eli Lillys new oral weight-loss pill, orforglipron , a GLP-1 drug that works like the widely used injectable medications
You cant sustain high profits in these massive drug markets because so many companies are vying for a piece of the pie, leading to intense competition where ultimately, no one makes significant money in the long run 24 Likes manoopatil May 5, 2025, 4:58pm 32 One source declared Q4FY25 results